title: Effects of mitiglinide and sulfonylureas in isolated canine coronary arteries and perfused rat hearts.
abstract: Our aim was to compare the cardiovascular effects of mitiglinide ((+)-monocalcium bis[(2S,3a,7a-cis)-alpha-benzylhexahydro-gamma-oxo-2-isoindolinebutyrate] dehydrate), a novel hypoglycemic drug, with those of glibenclamide and glimepiride, two sulfonylurea drugs. In isolated canine coronary arteries (organ-bath method), mitiglinide, glibenclamide, and glimepiride competitively antagonized the cromakalim-induced relaxation (pA2 values, 5.29, 7.36, and 7.49, respectively). In isolated perfused rat hearts (Langendorff method) subjected to a 12-min global ischemia followed by a 30-min reperfusion, mitiglinide (3 x 10(-6) mol/l) altered neither the change in coronary perfusion flow nor the alterations in cardiac functions associated with reperfusion. In contrast, both glibenclamide (3 x 10(-8) mol/l) and glimepiride (1 x 10(-7) mol/l) significantly reduced coronary perfusion flow after reperfusion. Moreover, at 30 min of reperfusion: (1) glibenclamide induced a significant increase in left ventricular end-diastolic pressure and significant decreases in left ventricular systolic pressure, left ventricular developed pressure, and the maximum first derivative of left ventricular pressure, while (2) glimepiride induced significant decreases in left ventricular developed pressure and the maximum first derivative of left ventricular pressure. Thus, the cardiovascular effects of mitiglinide (at least, in these rat and dog preparations) may be weaker than those of glibenclamide and glimepiride.
authors.affiliation: Research and Development Division, Kissei Pharmaceutical Co. Ltd., 4365-1, Kashiwabara, Hotaka, Azumino, Nagano, 399-8304, Japan. itaru_maruyama@pharm.kissei.co.jp
authors.forename: Itaru
authors.initials: I
authors.lastname: Maruyama
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Tomiyama
authors.forename: Kazuyasu
authors.initials: K
authors.lastname: Maruyama
authors.forename: Kazuma
authors.initials: K
authors.lastname: Ojima
authors.forename: Kumi
authors.initials: K
authors.lastname: Kobayashi
authors.forename: Mamoru
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Yamazaki
authors.forename: Masami
authors.initials: M
authors.lastname: Kojima
authors.forename: Nobuo
authors.initials: N
authors.lastname: Shibata
mesh_terms: D000818:Animals; D003326:Coronary Circulation / Q000187:drug effects; D003331:Coronary Vessels / Q000187:drug effects* / Q000502:physiology; D019806:Cromakalim / Q000494:pharmacology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005905:Glyburide / Q000494:pharmacology; D006321:Heart / Q000187:drug effects* / Q000502:physiology / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000494:pharmacology; D066298:In Vitro Techniques; D007211:Indoles / Q000494:pharmacology*; D054833:Isoindoles; D008297:Male; D015428:Myocardial Reperfusion Injury / Q000503:physiopathology; D010477:Perfusion; D051381:Rats; D017208:Rats, Wistar; D013453:Sulfonylurea Compounds / Q000494:pharmacology*; D013997:Time Factors; D014664:Vasodilation / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D007004:Hypoglycemic Agents; D007211:Indoles; D054833:Isoindoles; D013453:Sulfonylurea Compounds; D014665:Vasodilator Agents; D019806:Cromakalim; C057619:glimepiride; C087255:mitiglinide; D005905:Glyburide